Marco brughera
Non-Executive Director
Pharmaceutical Management
Jiangsu Hengrui Medicine Co., Ltd
Hong Kong
Biography
Dr. Marco Maria Brughera is Non-Executive Director of the Company. He has more than 30 years of business and management experience within the pharmaceutical industry. He is currently the Global Head of the SigmaTau Rare Disease Business Unit., a position he has held since October 2012. He is also President of Sigma-Tau Pharmaceuticals Inc., President of Sigma-Tau Research Switzerland S.A. and Chief Executive Officer of Sigma-Tau Pharma Ltd. Before that, he has served as Global Head of Research and Development (“R&D”) within SigmaTau. Previously he held leadership R&D positions with Farmitalia Carlo Erba S.p.A., Pharmacia Corporation, Pfizer, Inc. and Nerviano Medical Sciences S.r.1. both in Europe and the United States of America. From October 2013 he serves on the Board of Director of Soligenix, Inc., a company listed on the United States OTC Markets.
Research Interest
From December 2011 through January 2014, Dr. Brughera served on the Board of Directors of Gentium S.p.A., a then publicly traded biopharmaceutical company on the United States Nasdaq exchange. Dr. Brughera earned his degree in veterinary medicine from the University of Milan and is a European Registered Toxicologist..
